Sector News

Shareholder group critical as Roche and Novartis chiefs top Swiss pay table

October 9, 2014
Life sciences
(Reuters) – The bosses of drugmakers Roche and Novartis both earned more than 13 million Swiss francs ($13.6 million) last year, according to a study published on Wednesday, 18 months after the Swiss voted for some of the world’s strictest controls on executive pay.
 
The pay packets of Roche CEO Severin Schwan and Novartis counterpart Joe Jimenez topped the list of Switzerland’s best-paid managers and prompted criticism from shareholder group Ethos, which conducted the study.
 
“Double-digit sums are difficult to accept in Switzerland,” Ethos director Dominique Biedermann told reporters. “When Mr Schwan and Mr Jimenez earn 13 million in a good year, but not a record year, what will they earn in a record year?”
 
Last year Swiss voters backed proposals to give shareholders the power to veto executive pay proposals as well as banning big rewards for new and departing managers. Companies have until the end of 2015 to implement the measures.
 
Ethos said the initiative appeared to have slowed the growth in executive pay, with overall compensation staying broadly stable despite a sharp rise in company share prices and profit.
 
Roche’s Schwan earned 13.4 million francs, a drop of 13 percent from the previous year, while Jimenez’s Novartis remuneration was stable at 13.2 million francs.
 
Executive pay at Switzerland’s 100 biggest companies rose 2 percent last year, driven by an 8 percent rise in salaries in the financial services sector. Pay in other industries slipped by 1 percent.
 
Average CEO pay in Switzerland rose 4 percent to 3.4 million francs, while that of a non-executive chairman fell 7 percent to 1.2 million francs.
 
(Reporting by Caroline Copley; Editing by David Goodman)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”